Project Grant R01HL185725
Award Date 9/1/26
Completion Date 5/31/28
Dollars Obligated $1.8M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $1,540,621 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial inflammation, C-terminal SRC kinase dysregulation, and fibrosis in early pulmonary arterial hypertension. The award funds research into molecular mechanisms regulating fibroproliferative pulmonary vascular remodeling in early PAH, with particular focus on patients with inflammatory...
- The National Heart, Lung, and Blood Institute awarded Brown University $100,228 on December 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of chitinase 3-like-1 in pulmonary arterial hypertension pathogenesis. The project grant funds research into how the protein CHI3L1 contributes to immune and metabolic dysfunction underlying vascular remodeling in PAH, with particular focus on macrophage metabolism and pro-remodeling effects. The research...
- The National Heart, Lung, and Blood Institute awarded the University of Maryland, Baltimore $775,687 under Project Grant R01HL183332 on August 10, 2026, to support research on molecular drivers of pulmonary vascular remodeling in pulmonary hypertension with heart failure and preserved ejection fraction (PH-HFPEF). The research investigates beta-2 microglobulin (B2M) as a therapeutic target in PH-HFPEF. The project builds on findings that PH-HFPEF patients display elevated circulating B2M...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $676,602 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of LYVE1-expressing interstitial macrophage-driven vascular remodeling in pulmonary hypertension. The research examines the role of LYVE1+ interstitial macrophages (IMs) in pulmonary hypertension, a deadly, incurable disease of the pulmonary...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $1.774674 million on June 10, 2026, under Cardiovascular Diseases Research (CFDA 93.837) to investigate TBX4-driven pulmonary hypertension mechanisms and identify therapeutic targets. The project examines how heterozygous rare variants in TBX4, the second most common cause of heritable pulmonary arterial hypertension, lead to disease pathology. The research employs three integrated tools: ChIP-seq and...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Vanderbilt University Medical Center $341,280 on September 19, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a five-year mentored career development project investigating apoptosis resistance mechanisms in pulmonary arterial smooth muscle cells. Dr. Niedermeyer, under mentorship from Dr. Larissa Shimoda and Dr. Mahendra Damarla, will conduct hands-on laboratory research, complete...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $723,400 on August 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate asporin as a dual-pathway therapeutic target and biomarker for pulmonary arterial hypertension. The project, designated R01HL183171, addresses pulmonary arterial hypertension (PAH), a progressive and fatal vascular disease marked by pulmonary vascular remodeling and right ventricular failure,...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $264,750 on July 1, 2026, for a Project Grant (R03HL178552) under the Cardiovascular Diseases Research program (CFDA 93.837) to identify pathogenic somatic mutations in pulmonary arterial hypertension. The award funds research to determine whether somatic (acquired) mutations in disease-causing pathways contribute to PAH pathogenesis. The work proceeds through two approaches: analyzing cell-free DNA in circulating...
- The National Heart, Lung, and Blood Institute awarded The Johns Hopkins University $776,005 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to fund research on beta-hydroxybutyrate–mediated endothelial cell and skeletal muscle dysfunction in pulmonary arterial hypertension. The project, R01HL184469, runs through May 31, 2031, with work performed in Baltimore, Maryland. The research addresses the mechanisms linking mitochondrial dysfunction in lung...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...